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Background: Modeling and simulation is increasingly used to study pediatric
pharmacokinetics, but clinical implementation of age-appropriate doses lags behind.
Therefore, we aimed to develop model-informed doses using published
pharmacokinetic data and a decision framework to adjust dosing guidelines based on
these doses, using piperacillin and amikacin in critically ill children as proof of concept.
Methods: Piperacillin and amikacin pharmacokinetic models in critically ill children were
extracted from literature. Concentration-time profiles were simulated for various dosing
regimens for a virtual PICU patient dataset, including the current DPF dose and doses
proposed in the studied publications. Probability of target attainment (PTA) was compared
between the different dosing regimens. Next, updated dosing recommendations for the
DPF were proposed, and evaluated using a new framework based on PK study quality and
benefit-risk analysis of clinical implementation.
Results: Three studies for piperacillin (critically ill children) and one for amikacin (critically ill
pediatric burn patients) were included. Simulated concentration-time profiles were
performed for a virtual dataset of 307 critically ill pediatric patients, age range
0.1–17.9 y. PTA for unbound piperacillin trough concentrations >16mg/L was >90%
only for continuous infusion regimens of 400mg/kg/day vs. 9.7% for the current DPF dose
(80 mg/kg/6 h, 30 min infusion). Amikacin PTA was >90% with 20 mg/kg/d, higher than
the PTA of the DPF dose of 15mg/kg/d (63.5%). Using our new decision framework,
altered DPF doses were proposed for piperacillin (better PTA with loading dose plus
continuous infusion), but not for amikacin (studied and target population were not
comparable and risk for toxicity with higher dose).
Conclusions: We show the feasibility to develop model-informed dosing guidelines for
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complement literature and consensus-based dosing guidelines for off-label drugs in the
absence of stronger evidence to support pediatricians in daily practice.
Keywords: pharmacokinetics, model-informed dosing, clinical implementation, critically ill children, piperacillin,
amikacin
INTRODUCTION
The Dutch Pediatric Formulary (DPF) provides pediatric dosing
recommendations for all drugs used in children the Netherlands
(van der Zanden et al., 2017). This includes drugs used off-label
by indication and/or age group, but also drugs approved for use in
children. If emerging evidence suggests the labelled dose to be
suboptimal, the DPF adjusts the dose to reflect up-to-date
evidence. These best-evidence doses are based on a
standardized benefit-risk analyses using literature data,
including doses used in clinical trials and expert opinion. The
DPF overcomes the current information gap for physicians when
a medical need to prescribe a drug to children is evident and the
registered pediatric dose is lacking or believed suboptimal due to
emerging new data.
Drug disposition rapidly changes during growth and
development, due to maturation of the processes involved in
absorption, distribution, metabolism and excretion (Kearns et al.,
2003). Not addressing these differences between adults and
children might cause suboptimal exposure, lack of efficacy or
adverse effects in children (Kearns, 2010; Tuleu and Breitkreutz,
2013). Pediatric pharmacokinetic (PK) data, reflecting these age-
related changes can be used to simulate dosing regimens reaching
therapeutic and safe exposures. Indeed, model-informed dosing is
increasingly used to support dosing recommendations, but
implementation in clinical care of such dosing guidelines is
lagging behind (Darwich et al., 2017; Keizer et al., 2018).
Moreover, many pediatric PK publications do not include
dosing simulations and/or proposals for dosing.
We hypothesized that existing, published PK data can also be
used to generate dosing recommendations and be used to
optimize existing dosing recommendations for children, to be
implemented in clinical dosing guidelines, such as the DPF. The
aim of our study was to develop a framework using model-
informed doses based on published PK studies, as a
complementary tool to generate model-informed, evidence-
based dosing guidelines.
MATERIALS AND METHODS
Literature and Selection of Drugs
As proof of concept, we focused on the dosing regimens of
antibiotics in critically ill children, as concentration targets are
available, to enable concentration-based simulations (Tsai et al.,
2015). Moreover, these drugs are relatively well studied in
children with published pharmacokinetic data ranging from
well-validated population PK (pop-PK) studies including dose
simulations, to more basic studies simply reporting drug
concentrations (Hartman et al., 2019).
We selected publications using pop-PK modelling as these
models include interindividual variation (IIV) as a parameter.
This provided the possibility to study the full target range and
identify the risk of over- or underdosing with the simulated doses.
We extracted any information on model structure of the final
model, differential equations, covariate relationships, PK-
parameter estimates (volume of distribution (Vd) and
clearance (Cl)), IIV, and residual error model. Additionally,
we evaluated concentration-time profiles in the publications
for peak (Cmax) and trough (Cmin) concentrations in order
to compare our results to the published studies. Lastly, we
identified whether the publication provided a dose advice for
critically ill children.
This information was used to select suitable drug candidates
aiming to study one drug with and one drug without dosing
simulations and recommendations in the manuscript. Both drugs
had to have dosing recommendations in the DPF.
Generating Dosing Regimens
PK models were implemented in R and R-studio using the
published PK parameters (R version 3.6.2, R-studio version
1.2.1335, R Core Team 2013) with additional package
“mrgsolve” and evaluated using “ggplot2” (ggplot2, 2016;
Mrgsolve, 2020). Model codes were requested from the
authors of the included publication. We only received the
model code from De Cock et al. which was used to verify our
version of the model (De Cock et al., 2017). The models were
written in line with the “mrgsolve user guide.” Development and
evaluation of the rebuilt models was performed in three steps
(detailed in Step 1: Implementation of Models in a Standardized
R-Script, Step 2: Extrapolation; Generating a Dosing Advice, and
Step 3: Decision Framework for Best Evidence Dosing Guidelines):
Step 1: Implementation of Models in a Standardized
R-Script
The first step consisted of rebuilding the model as described in the
original article for a specific antibiotic. This step was performed to
check validity of the models, as rebuilding the original models
should provide similar concentration-time outcomes to the
published article. We used the dosing advices in the original
articles as input for the model.
R-scripts of the models were written in a fixed format
including covariate relationships, PK-parameter values,
population characteristics and specific dosing regimens (as
described above). Other model-specific characteristics such as
model structure, differential equations and error-models were
dependent on the number of compartments and the type of error
model presented in the article.
The R-scripts were checked for purposes of quality control by
two experienced pharmacokinetic modelers (RTH and SVB).
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This ensured the models in the script were correctly adapted and
represented the models of the original articles.
Step 2: Extrapolation; Generating a Dosing Advice
After evaluating the implementation of the model in step 1, a
dosing advice was generated based on simulated concentration-
time profiles, toxicity thresholds and the PK targets of efficacy
and/or safety.
Simulation Patient Population
For our simulations we used a virtual PICU patient dataset with
anonymous demographic and relevant covariate data of critically
ill children, 1 m–18 y of age, admitted to the PICU of the
Radboudumc in 2018. This was done to ensure we had a
virtual patient population that closely mimics the target
population for the new dosing regimen. Data were obtained
from the electronic patient records and included weight,
height, postmenstrual age, postnatal age, gender and eGFR
calculated with the creatinine-based revised Schwartz formula
(Schwartz et al., 2009). Patients were excluded if more than two of
the requested demographic characteristics were missing.
Based on the Dutch Law on Human Drug Research, formal
ethical approval by an institutional review board or informed
consent were not needed as anonymized clinical patient data
were used.
Concentration (PK) Targets
Different PK targets for the efficacy and safety of antibiotics are
used, dependent on the properties of the drug. Based on the drugs
chosen for the simulation we identified the optimal PK targets.
We used epidemiological cut-off values of minimal inhibitory
concentrations (MIC) as target values aiming for a clinically
relevant, worst-case scenario. For this we used the
epidemiological cut-off for MIC values provided by the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) for each drug. The relevance of protein binding
was evaluated and obtained from literature data of comparable
patient populations.
Dose Simulations
Using 100 iterations of the PICU simulation dataset,
concentration-time curves were created and compared to
Cmax, Cmin and IIV presented in the original articles.
Subsequently, simulations of concentration-time profiles were
performed for different dosing regimens.
First, the current dose in the Dutch Pediatric Formulary (DPF)
was simulated (Dutch Pediatric Formulary-Amikacin; Dutch
Pediatric Formulary-Piperacillin). For the drug with dose
advice in the paper(s) we also used the advised dose as input
for these simulations. For the drug without a dose advice in the
paper, several dosing regimens were examined for reaching the
determined PK-targets, using a “trial and error”-principle with
predefined dose increments, based on the drug’s DPF dose and
dose intervals of at least 12 h.We compared the simulation results
between the DPF dose and these “trial and error” doses.
Cross-checks of these doses were performed between the
different models for additional insight in applicability and
robustness. Additionally, probability of target attainment
(PTA) was determined by the proportion of patients that
reach selected target concentrations for safety and/or efficacy.
PTA was determined for current and selected optimal dosing
regimens, in order to quantify the improvements in PTA of a new
dosing regimen.
Step 3: Decision Framework for Best
Evidence Dosing Guidelines
In order to aid the possible implementation of our model-
informed doses as best-evidence dosing guidelines of our
simulations, we determined the following framework to
evaluate the models. The following questions were aimed to
evaluate the level of uncertainty of the model-informed doses
and determine the doses with the best benefit-risk ratio for the
intended population:
(1) What is the level of certainty of the target concentrations?
(2) What is the clinical risk of over- or underdosing?
(3) What is the level of certainty of the model output?
(4) Does the currently advised DPF dose result in adequate
(simulated) target exposure?
(5) Which dose results in better target exposure, is this a
significant improvement?
(6) Is the proposed dose practical?
(7) Is the population in the published PK model comparable to
the simulated population (e.g., with respect to demographics,




Literature and Selection of Drugs
Piperacillin and amikacin were selected as the best drug
candidates for this study, as piperacillin has three available
pop-PK models, all providing a dose advice for critically ill
children (Nichols et al., 2015; De Cock et al., 2017; Béranger
et al., 2018) and one published amikacin pop-PK model was
available, but this study did not provide a dose advice for critically
ill children (Sherwin et al., 2014).
Pop-PK models were available for piperacillin from studies by
Béranger et al., De Cock et al. and Nichols et al., which included
67, 47, and 12 PICU patients, respectively (Nichols et al., 2015; De
Cock et al., 2017; Béranger et al., 2018). Age of patients ranged
from 1 m to 18 y, and patients with renal dysfunction were either
excluded beforehand or not included in the final study. Béranger
and Nichols identified piperacillin PK was best fitted by a one
compartment model, De Cock developed a 2-
compartmental model.
The 2-compartment amikacin model by Sherwin et al. included
232 amikacin concentrations from 70 critically ill, pediatric burn
patients, with ages ranging from 6m up to 17 y (17). An overview
of model and patient characteristics is shown in Table 1.
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Simulation Patient Population
After exclusion of duplicate entries and patients with missing
demographic data, the patient dataset included 307 patients in
total, with a median age of 4.9 y (Table 2). Creatinine
concentrations were available for 77 patients, with a median
eGFR of 115.2 ml/min/1.73 m2. Disease severity scores (Pediatric
Logistic Organ Dysfunction (PELOD)-2 scores), which were a
covariate in the Béranger piperacillin model, could not be
obtained from our hospital records, so the mean population
value from the Béranger study (PELOD-2  4) was used
(Béranger et al., 2018).
Concentration (PK) Targets for Selected
Drugs
The PK target associated with piperacillin efficacy is the
percentage of time the unbound plasma concentration
exceeded the minimal inhibitory concentration (%fT/MIC),
which should be 100% based on latest consensus (Nichols
et al., 2015; De Cock et al., 2017; Béranger et al., 2018). For
our simulations we used a target concentration of 16 mg/L, which
is the clinical breakpoint of Pseudomonas aeruginosa, as a worst-
case scenario [European Committee on Antimicrobial
Susceptibility Testing (EUCAST)]. The fraction of unbound
piperacillin was assumed to be 70% (Piperacillin - Summary of
Product Characteristics), similar to the assumed level of protein
binding in the models (Nichols et al., 2015; De Cock et al., 2017;
Béranger et al., 2018). The PTA for reaching the piperacillin PK-
target (unbound Cmin > 16 mg/L) was assessed for the advised
dosing regimens by Béranger, de Cock, Nichols and the DPF dose
across the three models. Overall PTA was defined as the mean
PTA across all models.
For amikacin a Cmax/MIC-ratio of 8–10 is the most
commonly defined PK target for efficacy and associated with
optimal bacterial killing (Tsai et al., 2015). Additionally, the safety
target for amikacin is a Cmin < 5 mg/L, which is associated with a
reduced risk of ototoxicity and nephrotoxicity (Zorginstituut
Nederland. Amikacine. Farmacotherapeutisch Kompas, Roberts
et al., 2012). Sherwin et al. used target Cmax and Cmin of
25–30 mg/L and 4–8 mg/L, respectively (Sherwin et al., 2014).
As the epidemiological cut-off value obtained from EUCAST for
most bacteria is 8 mg/L [European Committee on Antimicrobial
Susceptibility Testing (EUCAST)] we used a target Cmax of
60–80 mg/L to ensure the target Cmax/MIC ratio to be at least
8, a target also used in critically ill adults with severe infections (de
Montmollin et al., 2014). Unbound amikacin concentrations were
not taken into account, as amikacin protein binding is negligible
(Amikacin Summary of Product Characteristics SmPC, 2020).
Dose Simulations - Piperacillin
As input for the simulations we used the dosing advice provided
in the articles: Béranger et al. (Béranger et al., 2018) advised
400 mg/kg/d as a continuous infusion, De Cock et al. (De Cock
et al., 2017) advised a loading dose of 75 mg/kg followed by a
400 mg/kg/d continuous infusion, and Nichols et al. (Nichols
et al., 2015) advised 400 mg/kg/d as extended 3-h intermittent
infusions every 6 h.
TABLE 1 | Overview of study characteristics, populations, PK parameters and dose advice in the used pop-PK models.
Author Drug Dose regimen used in
study





PK parameters Dose advice
Béranger PIP 300 mg/kg/d, 4 daily doses,
30 min infusion
67 critically ill children 2.3–2.6 y (1–18 y) Cl: weight, eGFR PIP Cl 0.18 L/kg/h 400 mg/kg/d CON or EXT
11.9–13.7 kg
(2.7–53 kg)
Vd: PELOD-2 PIP Vd 0.351 l/kg
De Cock PIP 300 mg/kg/d, 4 daily doses,
5–30 min infusion
47 critically ill children 2.83 y (2 m–15 y) Cl: weight, PMA PIP Cl 0.25 L/kg/h 75 mg/kg loading dose
+400 mg/kg/d CON14 kg (3.4–45 kg) Vd: weight PIP central Vd 0.13 L/kg,
peripheral Vd 0.11 L/kg
Nichols PIP 300 mg/kg/d, 3 daily doses,
3 h infusion
12 critically ill children 5 y (1–9 y) Cl: weight PIP Cl 0.199 L/kg/h 100 mg/kg every 6–8 h as
EXT18.3 kg
(9.5–30.1 kg)
Vd: - PIP Vd 0.366 L/kg
Sherwin AMI 10–20 mg/kg/d, 2–4 daily
doses, 30 min infusion
70 critically ill pediatric
burn patients
4.5 y (0.5–17 y) Cl: weight AMI Cl 0.085 L/h/kg No dose advice
20 kg (8–90 kg) Vd: weight AMI central Vd 0.239 L/kg,
peripheral Vd 0.573 L/kg
AMI, amikacin; Cl, clearance; CON, continuous infusion; eGFR, estimated glomerular filtration rate; EXT, extended infusion; PELOD-2, Pediatric Logistic Organ Dysfunction two score; PIP,
piperacillin; PMA, postmenstrual age; Vd, volume of distribution.
TABLE 2 | Demographic and clinical characteristics of the Radboudumc PICU-
dataset from 2018 (n  307).





Postnatal age 4.9 y (1.2–11.5) [0.1–17.9]
Age categories
1 m–1 y 66 (21.5%)
1–2 y 40 (13.0%)
2–4 y 30 (9.8%)
4–8 y 59 (19.2%)
8–12 y 39 (12.7%)
12–18 y 73 (23.8%)
Weight 18.0 kg (10.0–38.0) [2.1–98.0]
eGFR (n  77) 115.2 ml/min/1.73 m2 (93.5–143.1) [20.9–196.2]
PICU, pediatric intensive care unit; eGFR, estimated glomerular filtration rate.
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Simulated concentration-time profiles for piperacillin were
compared to concentration-time plots in the original
publications. Our simulations showed reasonable
representation of median Cmax, Cmin and interindividual
variability in the original studies. Concentration-time profiles
of these simulations and cross-checks between different models
and piperacillin dosing regimens, are presented in Figure 1.
Both continuous dosing recommendations, by Béranger and
De Cock, resulted in the highest Cmin concentrations. For the
dosing regimen of Béranger steady-state median (95% prediction
interval) piperacillin concentrations were 51.2 mg/L
(20.0–134.0), 54.8 mg/L (33.8–91.1) and 59.8 mg/L
(20.3–107.2) in the models of Béranger, De Cock and Nichols,
respectively (Figure 1, first row). The dose regimen proposed by
De Cock et al. (400 mg/kg/d as continuous infusion with a
75 mg/kg loading dose) yielded similar median concentrations
51.4 mg/L (19.7–132.6), 54.8 mg/L (33.5–90.5) and 59.8 mg/L
(20.2–107.8) (Figure 1, second row), but reached therapeutic
concentrations faster. Contrarily, regimens using intermittent
doses, as advised by Nichols et al. and the DPF dose, did not
reach median Cmin > 16 mg/L (Figure 1, third and fourth row).
PTA of piperacillin at a MIC of 16 mg/L was > 90% in for both
continuous dosing regimens by Béranger and de Cock (Figure 2)
across all three models. The intermittent dosing regimen of
Nichols (400 mg/kg/d, 6 h dosing interval, extended infusion
of 3 h) showed an overall PTA of 36.7%, ranging from 19.2%
in the de Cock model to 47.7% in the Nichols model. However,
this is still markedly higher than what is reached with the current
DPF dosing regimen, with an overall PTA of 9.6%, ranging from
0.6–25.8% in the Nichols and Béranger model respectively.
Dose Simulations - Amikacin
There was no dosing advice presented in the Sherwin article, so
the starting point for the simulations was the dosing advice in the
DPF (15 mg/kg every 24 h) and the highest registered dose
(20 mg/kg/d) in the summary of product characteristics
(SmPC) (Amikacin Summary of Product Characteristics
SmPC). Subsequently, a trial and error-method resulted in a
concentration course over time, for which the predetermined PK-
targets for effectivity and toxicity were reached (Figure 3).
Dosing regimens of 10mg/kg/24 h, 15mg/kg/24 h, 10mg/kg/
12 h, 20 mg/kg/24 h and 25mg/kg/24 h were tested. The dosing
FIGURE 1 | Unbound piperacillin concentrations over 48 h for models of Béranger, De Cock and Nichols. The black line represents the median piperacillin
concentration, the shaded grey area the 95% prediction interval, and the dotted line the target Cmin of >16 mg/L. Columns represent the simulations of a single model
(panel (A), (D), (G) and (J) for the Béranger model, panel (B), (E), (H) and (K) for the De Cock model and panel (C), (F), (I) and (L) for Nichols model). The rows represent
different dosing recommendations from the different models (panel (A), (B) and (C) for the dose proposed by Béranger (400 mg/kg/d as continuous infusion), panel
(D), (E) and (F) for the dose proposed by De Cock (75 mg/kg loading dose +400 mg/kg/d as continuous infusion), panels (G), (H) and (I) for the dose proposed by
Nichols (100 mg/kg/6 h as extended infusion during 3 h) and panels (J), (K) and (L) for the current DPF dose (80 mg/kg/6 h as bolus infusion)).
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regimen of 20 mg/kg every 24 h, administered over 30 min, reached
predetermined PK-target in most patients, with a simulated Cmax
of 70.2 mg/L (95% prediction interval 51.7–97.5) and for Cmin
1.1 mg/L (95% prediction interval 0.3–2.3). Other dosing regimens
demonstrated suboptimal results: all dosing regimens under
20 mg/kg/dose failed to reach appropriate Cmax concentrations
(33.9 mg/L (24.6–45.0) for 10 mg/kg/dose and 50.6 mg/L
(35.5–68.3) for 15 mg/kg/dose). On the other hand, a regimen of
25 mg/kg/24 h resulted in supratherapeutic Cmax concentrations
(82.3 mg/L (55.9–107.5)). PTA of the safety target (Cmin < 5 mg/L)
was 100% for all simulated dosing regimens.
Probability of target attainment (PTA) was simulated for the
currently proposed dosing regimen from the DPF (15 mg/kg/
24 h) and our proposed dose of 20 mg/kg/24 h (Figure 4). For an
MIC of 8 mg/L, the current dose reaches a PTA of 63.5%, while a
dosing regimen of 20 mg/kg/24 h reaches a PTA of 96.2%.
Differences in PTA between these two dosing regimens for
other MICs was minimal.
Decision Framework for Best Evidence
Dosing Guidelines
Piperacillin
(1) What is the level of certainty on the target concentrations?
Moderate to high, based on EUCAST MIC concentrations and widely
accepted definition of target attainment %fT/MIC >100. The percentage
unbound drug is estimated, in line with other studies of this drug in this
population.
(2) What is the clinical risk of over- or underdosing?
In general penicillins show a relatively mild safety profile. The
additional risk of overdosing of tazobactam, the accompanying drug
in all piperacillin formulations, should be taken into account. However,
this also appears to be relatively safe in higher than licensed doses
(McDonald et al., 2016). Underdosing may result in ineffective
bacterial clearance, which weighs heavier than the relatively mild side-
effects, especially in critically ill patients.
(3) What is the level of certainty of the model output?
Simulation of concentrations using all three models resulted in similar
exposures as in the publications. Moreover, all studies used state of the art
internal validation methods. However, interindividual and residual
variability was relatively large in all three models, which widens the
prediction intervals of our simulations.
(4) Does the currently advised DPF dose result in adequate target
exposure?
No, only 9.6% reaches the target Cmin concentration of >16 mg/L
with the current intermittent dosing regimen of 320 mg/kg/d as
intermittent dose.
(5) Which dose results in better target exposure, is this a
significant improvement?
FIGURE 2 | Probability of target attainment (PTA) for piperacillin with
different dosing regimens. The different lines represent the average PTA
across the three models at different MICs for the different dosing regimens
(Béranger dose  yellow, dashed line, downward facing triangle; De
Cock dose  blue, dash-dotted line, upward facing triangle; Nichols dose 
red, dashed line, diamonds; DPF dose  green, solid line, squares). (CI,
continuous infusion; DPF, Dutch Pediatric Formulary; EXT, extended infusion;
LD, loading dose; MIC, minimum inhibitory concentrations).
FIGURE 3 | Amikacin concentration-time curves simulated over 48 h
using the PK model of Sherwin et al. The black line represents the median
amikacin concentration, the dark grey area around the line the 95% prediction
interval. The light grey band represents the target Cmax (60–80 mg/L)
and the dotted line represents the target Cmin (<5 mg/L). Panels (A)–(E)
represent different tested dosing regimens, including the currently advised
DPF dose (panel (C)).
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400 mg/kg/d performed significantly better than the DPF daily dose of
320 mg/kg/d. Continuous infusion performed best (PTA > 90%), and
when combined with a loading dose of 75 mg/kg this is the most optimal
dosing regimen to reach fast and steady therapeutic concentrations.
(6) Is the proposed dose practical?
Continuous infusions may not be practical in critically ill children
where venous access is always challenging and limited. Intermittent doses
using an extended dosing interval may be more practical in clinical
practice.
(7) Is the population in the published PK model comparable to
the simulated population (e.g., with respect to demographics,
severity of illness, underlying disease)? If not, will this impact
the dosing requirements?
The models all included critically ill children with mixed underlying
reasons for ICU admission which did cover most of the pediatric age
range, but with a slightly lower median age compared to our simulation
cohort. Therefore, these results might be applicable to critically ill
children, but less applicable for non-critically ill children, although
piperacillin-tazobactam will likely only be prescribed to severely ill
children. Additionally, we used a worst-case scenario for MIC,
whereas actual MIC targets may differ for other bacteria or other
areas where microbial resistance may be different (Woksepp et al., 2016).
(8) Overall conclusion for piperacillin:
According to our simulations, the proposed optimal dosing regimen
for critically ill children is a loading dose followed continuous infusion to
reliably reach target concentrations shortly after diagnosis (De Cock
et al., 2017). In situations where continuous infusion is not possible, the
alternative option would be the Nichols dosing regimen of 400 mg/kg/d
as an extended 3-h infusion (Nichols et al., 2015). For non-critically ill
children, the current dosing advice could be continued, although a similar
simulation study for non-critically ill children also suggested a slightly
higher dose of 360 mg/kg/d and extended infusion in 2 h to reach
adequate targets (Thibault et al., 2017). Additionally, as dose-related
toxicity is limited, harmonizing the dose across the pediatric populations
would be more practical.
Amikacin
(1) What is the level of certainty on the target concentrations?
Moderate, based on EUCAST MIC concentrations and a common
definition of target attainment: Cmax/MIC ratio to be at least 8, a
target also used in critically ill adults with severe infections. However,
others use less aggressive target Cmax, possible in a setting with less
microbial resistance. Additionally, although Cmax/MIC is the most
commonly used target, a recent publication also proposes AUC/MIC
to be the optimal target for aminoglycoside efficacy (Bland et al., 2018).
(2) What is the clinical risk of over- or underdosing?
Amikacin’s dose-related toxicity is kidney failure and ototoxicity
related to the Cmin. A meta-analysis of amikacin side-effects in adults
shows a prevalence of nephrotoxicity and irreversible ototoxicity of 5.3%
and 8.6%, respectively (Jenkins et al., 2016), which may cause a major
burden on healthcare and patient lives. Underdosing may result in
ineffective bacterial clearance, and potentially life-threatening
infections and/or sepsis. Therefore, therapeutic drug monitoring
(TDM) is routinely advised for aminoglycosides, so the dosing
regimens of an individual patient can be adjusted to ensure
therapeutic, non-toxic amikacin exposure.
(3) What is the level of certainty of the model output?
Moderate. Simulations of concentrations using the model parameters
resulted in similar exposures as published. Moreover, the study used state
of the art internal validation methods, but external validation is missing.
(4) Does the currently advised DPF dose result in adequate target
exposure?
No, the DPF dose results in a PTA of 63.5% at MICs of 8 mg/L.
(5) Which dose results in better target exposure, is this a
significant improvement?
20 mg/kg/d results in better PTA at the same MIC (96.2%), with
similar (non-toxic) Cmin. For patients infected with a micro-organism of
this MIC this would be a significant improvement. However, target
attainment for different MICs is comparable between 15 and 20 mg/kg/d.
(6) Is the proposed dose practical?
Yes.
(7) Is the population in the published PK model comparable to
the simulated population (e.g., with respect to demographics,
severity of illness, underlying disease)? If not, will this impact
the dosing requirements?
FIGURE 4 | Probability of target attainment (PTA) for amikacin for two
dosing regimens at different MICs. The two presented dosing regimens are
the current DPF recommendation of 15 mg/kg/24 h (pink, dashed line, circles)
and our optimally simulated dose of 20 mg/kg/24 h (light blue, solid line,
triangles).
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The model population consisted of a highly specific subgroup of
critically ill children, pediatric burn patients (Sherwin et al., 2014). It is
known that due to e.g., fluid retention, pharmacokinetics may differ in
patients with extensive burn injury, resulting in lower exposures. Hence,
the data cannot be automatically extrapolated to non-burned critically ill
children. The study does cover the full pediatric age range within their
cohort.
(8) Overall conclusion for amikacin:
Although the simulated dosing regimens suggested a higher daily dose
(20 mg/kg/d) than the current DPF, the difference in patient population,
potentially explaining the difference with the current DPF dose, the risk
of dose-related toxicity in another (critically ill) population, and the
relatively small benefit limited to MICs of 8 mg/L does not support an
overall change in DPF dose. In critically ill pediatric burn patients, this
higher dose could be considered, but only in the absence of renal failure
and with strict TDM.
DISCUSSION
In this proof of concept study we explored the feasibility to
develop a framework to aid the implementation of model-based
dosing guidelines using published pop-PK models in critically ill
children, with piperacillin and amikacin as examples. We found
that this model-based strategy is feasible to use in practice and we
were able to compare dosing advices from three different models
of piperacillin, which showedmarked differences in PTA between
doses advised in the studies. Additionally, we generated a
simulated dose for amikacin, an antibiotic for which the
dosing advice was not provided in the paper describing the
model (Sherwin et al., 2014). Lastly, we used a standardized
framework of questions to explore whether these findings warrant
a change in the dosing regimen advised by the DPF or other
pediatric drug handbooks.
Simulations for both antibiotics suggest that the current DPF
dosing regimen results in a suboptimal target attainment in
critically ill children. For piperacillin, the evidence is more
apparent, as all three articles propose at least 400 mg/kg/d for
adequate exposure specifically for critically ill children (Nichols
et al., 2015; De Cock et al., 2017; Béranger et al., 2018). These
results might warrant an alteration in the DPF dosing
recommendation, as supported by our decision framework,
which also takes study quality and clinical benefit and risks
into account.
For amikacin, while the simulation suggests a higher daily
dose, our decision framework does not support a change in
dosing regimen. Our simulation results may be only applicable
for critically ill children with severe burn injury, a highly
specific subgroup with unique pharmacokinetic challenges
(Sherwin et al., 2014). Severe burn injury induces several
pathophysiological alterations, including capillary leak,
extreme interstitial edema, hypovolemia and reduced organ
perfusion in the early phase (Udy et al., 2018). Furthermore,
treatment of severe burn patients revolves around large
volumes of IV fluid resuscitation to increase intravascular
pressure and organ perfusion, but also leading to additional
extracellular fluid accumulation (Udy et al., 2018). Both
pathophysiological alterations and therapies contribute to
markedly higher Vd of hydrophilic drugs, like amikacin
(Tsai et al., 2015). Additionally, the second phase of burn
injury typically involves organ hyperperfusion, which may
cause augmented renal clearance making critically ill, burn
patients a highly challenging subgroup to dose correctly (Udy
et al., 2014; Udy et al., 2018).
In the Sherwin cohort these pharmacokinetic changes are
evident, as total amikacin Vd was markedly higher (0.81 L/kg)
compared to non-burned infants (0.337 L/kg) (Treluyer et al.,
2002). The most commonly used PK-target for amikacin efficacy
(Cmax/MIC), is largely influenced by this larger Vd resulting in a
higher dose to reach similar Cmax. Additionally, aminoglycosides
concentrations are subject to routine TDM, so potential reduced
exposure with the current regimen can corrected when necessary.
While simultaneously, a higher dose may result in irreversible
toxicity in non-burn patients. Therefore, a nationwide dose
alteration might not be warranted at the moment.
Pharmacokinetic studies of other antibiotic agents in critically
ill children, also suggest similar reduced (simulated) target
attainment (Jenkins et al., 2016; McDonald et al., 2016; Bland
et al., 2018). Unfortunately, a direct and practical translation to
clinical practice is lacking. Not only are model-informed doses
frequently not proposed in these manuscripts, even if they are,
authors are very reluctant to support clinical implementation as
they consider further validation unnecessary. We do support high
quality data to establish with large certainty the correctness of
model-informed doses (Ince et al., 2009). At the same time, in the
absence of more data and the practice of off-label prescribing, not
using existing pharmacokinetic data to add to the current
evidence-base that supports doses used in real-life clinical care
is a missed opportunity. Our decision framework helps to
interpret study results with the aim to translate findings to the
clinical setting, in a similar risk-benefit analysis that is currently
applied by the DPF (van der Zanden et al., 2017). This allows for a
thorough evaluation of study results not only for pharmacological
efficacy, but also for toxicity, practicality and assessment of
external validity of research findings to another clinical setting.
Although our model-based approach to generate evidence-
based dosing recommendations seems feasible, it comes with
some limitations. The quality of the model-based results is largely
influenced by the quality and population of the data provided in
literature. We used only pop-PK model data to ensure the highest
possible quality of PK parameter estimates, but the models were
not externally validated and for amikacin the only available PICU
study was performed in burn patients which limits the external
validity of our findings. Ideally, future research towards this
approach should also include lower-quality data, for example
non-compartmental estimates of Vd and Cl, but accurate
simulations of drug exposure might prove difficult with
suboptimal data. Secondly, this method benefits from
established target concentrations that correlate with either
effect, drug toxicity or both, which is not available for all drug
classes. Thirdly, we have generated a dosing advice using a trial-
and-error approach and with a relatively small virtual PICU
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cohort, which might be further optimized by more advanced
modelling techniques and a larger database of virtual patients
including more covariate data. Lastly, although we aimed to close
the knowledge gap for evidence-based dosing in children with
limited resources, it is of the essence to not abandon the drug
dosing quality improvement cycle and evaluate the updated
dosing regimens (Ince et al., 2009).
Ideally all dosing recommendations would be based on the
most robust form of pharmacokinetic evidence, e.g., from large
clinical PK trials or robust pop-PK studies. Additionally, routine
TDM strategies could be applied in clinical practice to ensure
therapeutic and non-toxic drug exposure after the starting dose
has been given. Given the large inter-individual variability in
critically ill children, the relatively well-known PK targets
associated with efficacy and/or safety, and the inability to
judge therapeutic effect by other parameters, routine TDM for
antibiotics could be beneficial in this patient population
(Wallenburg et al., 2020). Ultimately, model-informed
precision dosing applications that are currently under
development can translate these robust PK data into tailored
dosing regimens for an individual patient, using TDM samples
and Bayesian feedback to further improve and individualize
dosing of antibiotics in special populations (Darwich et al.,
2017; Keizer et al., 2018).
However, reality shows overall dosing recommendations for
children regularly need to be made using suboptimal, best-
evidence data. In this dilemma between costly, high-grade,
patient-specific evidence and pragmatic, best-evidence dosing
guidelines, our method could be used as an additional tool to
improve current dosing guideline practices. This method is
relatively easy to apply by professionals involved in pediatric
dosing guidelines, even without prior modelling experience, as it
only requires basic knowledge on model structures and R. Within
current practice, it can serve to compare multiple models and can
be used to simulate dosing regimens using real PK data. Future
studies regarding this method should focus on the applicability in
a clinical setting, like the DPF. If not implemented properly, this
might harm reproducibility and ease of use in practice.
CONCLUSION
Our framework using existing PK data to established model-
informed doses can be used as a relatively affordable, easy and
efficient simulation tool in special populations, and can be used in
conjunction with current strategies for developing evidence-based
dosing recommendations. We have shown for piperacillin in
critically ill children a higher dose might be warranted. In
contrast, for amikacin population differences, uncertainty on
target exposure, increased risk of toxicity and small benefits, do
not support a change in the clinical dosing guidelines. Although
this method cannot replace well-designed clinical trials, it can
prove to be valuable, especially for the pediatric population, where
off-label prescribing remains very prevalent.
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